intensive care unit (ICU) is high, SDD is not widely used in clinical practice. SDD has been the subject of strong controversies among detractors and advocates of the manoeuvre. SDD opponents still rely on historical arguments against its use, such as the lack of any effect on mortality and the emergence of resistance. This article will review the evidence on the efficacy of SDD and the issue of emergence of resistance, using data from RCTs and meta-analyses of SDD.
What is SDD
SDD is a prophylactic strategy designed to prevent or minimize endogenous and exogenous infections, and to reduce mortality in critically ill patients. The aim of SDD is to prevent or eradicate, if present, the oropharyngeal and intestinal abnormal hSr Proceedings in intensive care and cardiovascular Anesthesia 2012, vol. 4 carriage of potentially pathogenic microorganisms (PPMs), such as Gram-negative aerobic microorganisms (AGnB), methicillin-sensitive Staphylococcus aureus and yeasts (16) (17) (18) . The philosophy of SDD has some fundamentals (16) (17) (18) : -critical illness importantly impacts the body flora promoting a shift from normal to abnormal carriage and from low-grade carriage to high-grade carriage, i.e. overgrowth of normal and abnormal flora; -gut overgrowth (i.e. ≥10
5 colonies per ml of saliva or faeces), in particular due to abnormal AGnB, is a critical event which precedes endogenous infections, and is a risk factor for antimicrobial resistance; -a limited range of 15 PPMs is responsible for the majority of infections in ICU, and SDD mainly impacts these microorganims; -most ICU infections are primary endogenous infections, followed by secondary endogenous and exogenous infections; -the use of the full four components protocol of SDD is crucial. SDD selectively targets both normal (e.g. methicillin-sensitive S. aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, Candida albicans) and abnormal flora (e.g. Klebsiella, Enterobacter, Citrobacter, Serratia, Proteus, Morganella, Pseudomonas, Acinetobacter species, and methicillin-resistant S. aureus). By design SDD does not cover low-level pathogens, such as anaerobes, viridans streptococci, enterococci, and coagulase-negative staphylococci, which rarely cause infections during ICU stay. The full protocol of SDD classically consists of four components (18) (12) . Eighteen patients should be treated with SDD to save one life. Remarkably, in meta-analyses with a small sample size the reduction in mortality was not significant (5, 8, 14) . There are two large Dutch RCTs with the endpoint of mortality (20, 21) . In the first the risk of mortality was reduced by 40% in the unit where SDD was administered to all patients (21 clustered RCT from The netherlands the proportion of patients with AGnB in rectal swabs that were not susceptible to the marker antibiotics was lower with SDD than with standard care or SoD (20) . Remarkably, a post-hoc analysis of the same Dutch RCT, explored the incidence of bacteremia and lower respiratory tract colonization due to highly resistant microorganisms (HRMos), in particular AGnB (27) . Bacteremia due to HRMos was significantly reduced by SDD compared with SoD (oR 0.37; 95% CI 0.16-0.85), and lower respiratory tract colonization due to HRMos was less with SDD (oR 0.58, 95% CI 0.43-0.78) than SoD (oR 0.65, 95% CI 0.49-0.87) compared with standard care. In an ecological survey (28) undertaken during the study period of the Dutch RCT (20) , an increase in resistance after SoD and SDD discontinuation was observed. This seems to contradict the reduction in resistance demonstrated in the main study. However, that ecological study has some important limitations. first, the study used a point-prevalence method in which all patients in the unit, whether enrolled or not in the study, were included. Second, the change in resistance could also be due to a simultaneous change of the resistance spectrum in patients admitted to the hospital, as admission cultures were included in the study. finally, the survey showed that AGnB resistant to the marker antibiotics in the respiratory tract were significantly lower during SDD/SoD than during the pre-and post-intervention periods, and AGnB resistance to ciprofloxacin and tobramycin in rectal swabs was significantly lower during SDD than during standard care/SoD. These findings confirm that SDD does not increase the resistance problem, but actually reduces it, and that SDD was superior to SoD and standard care in controlling the emergence of resistance.
cant reduction in the odds of death by 78% (oR 0.22, 95% CI 0.12-0.43) (23) . Three RCTs investigating gastroesophageal surgery were pooled together in a metaanalysis which showed that SDD reduced pneumonia rate by 64% (oR 0.36, 95% CI 0.19-0.69) (24) . A meta-analysis of SDD in transplant recipients found a significant reduction of infections due to AGnB and yeasts (oR 0.16, 95% CI 0.07-0.37) (8).
The reduction was not significant when all infections were analysed, owing to a substantial number of infections due to lowlevel pathogens, such as enterococci and coagulase-negative staphylococci, which are intrinsically not covered by SDD. The small sample size may explain why mortality was not significantly reduced. four pediatric RCTs were included in a recent meta-analysis. Pneumonia was significantly reduced by SDD (oR 0.31, 95% CI 0.11-0.87), whilst overall mortality was not (oR 1.18, 95% CI 0.50-2.76) (25) . However, the results of all these analyses should be interpreted with caution due to the low number of studies and patients included.
Resistance
AGnB resistance was the endpoint of four RCTs (4, 20, 21, 26) . During an outbreak of K. pneumoniae producing extended spectrum beta-lactamase in a french ICU, SDD significantly reduced both carriage and infections due to this microorganism (26) . Similarly, SDD cleared gut overgrowth of carbapenem-resistant K. pneumoniae in the Beer-Sheva ICU, Israel (4). A Dutch mono-centre RCT of about 1000 patients found that carriage of AGnB resistant to imipenem, ceftazidime, ciprofloxacin, tobramycin and polymyxins occurred in 16% of patients receiving parenteral and enteral antimicrobials, compared to 26% of control patients that received parenteral antibiotics only with a relative risk of 0.6 (95% CI 0.5-0.8) (21) . In the multi-center By design, SDD does not cover MRSA, and, therefore, may promote carriage and infection due to this PPM. There are seven RCT conducted in ICUs in which MRSA was endemic during the study and demonstrated a trend toward higher MRSA infection rates in patients receiving SDD (29) . Under these circumstances, the original SDD component requires the addition of oropharyngeal and/or intestinal vancomycin. Interestingly, three studies (30-32) using 2 g of 4% vancomycin gel or paste and/or 2 g of vancomycin solution added to the nonabsorbable PTA component demonstrated that prevention and eradication of carriage and overgrowth of MRSA was followed by the control of MRSA infection, transmission and outbreaks. Severe infection, including MRSA pneumonia, were significantly reduced using enteral vancomycin (32, 33) . Although, studies on AGnB resistance have not led to an increased resistance problem, clinicians should be aware that highly resistant microorganisms may be selected during SDD, in particular in ICUs where these microorganisms are endemic. Therefore, surveillance samples of throat and rectum are mandatory to detect resistance at an early stage.
Costs
Costs were reduced in the majority of SDD RCTs, including cost per survivor (34) . In the recent Dutch trial, although the median number of defined daily doses of systemic antibiotics per patient-day did not significantly differ among SDD, SoD and standard care, the use of carbapenems, quinolones and lincosamides was reduced in SDD compared with SoD and standard care (21 
